Skip to main content

Table 1 Clinicopathologic characteristics of patients treated with ultra-early or early salvage ADT

From: Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer

Variable

Ultra-early salvage ADT(n = 51)

Early salvage ADT(n = 70)

p-value

Median age at prostatectomy, yr (IQR)

65 (61 - 69)

67 (60.75 - 72.25)

0.2992

Age at prostatectomy, no. (%):

  

0.0804

 <70 yr

39 (76.5)

43 (61.4)

 

 ≥70 yr

12 (23.5)

27 (38.6)

 

Median preoperative PSA, ng/ml (IQR)

10.65 (7.3 - 15.56)

9.55 (6.3 - 12.07)

0.1903

Preoperative PSA, no (%):

  

0.6041

 <20 ng/ml

46 (90.2)

61 (87.1)

 

 ≥20 ng/ml

5 (9.8)

9 (12.9)

 

Pathologic Gleason score, no. (%):

  

0.3256

 ≤6

12 (23.5)

23 (32.9)

 

 7

28 (54.9)

38 (54.3)

 

 8-10

11 (21.6)

9 (12.9)

 

Pathologic tumor stage, no. (%):

  

0.8619

 T2

32 (62.7)

45 (64.3)

 

 T3/4

19 (37.3)

25 (35.7)

 

Extraprostatic extension, no. (%)

17 (33.3)

25 (35.7)

0.7859

Lymphovascular invasion, no. (%)

13 (25.5)

16 (22.9)

0.7376

Positive resection margin, no. (%)

37 (72.5)

43 (61.4)

0.2019

Seminal vesicle invasion, no. (%)

2 (3.9)

2 (2.9)

0.7464

Perineural invasion, no. (%)

35 (68.6)

43 (61.4)

0.4139

Median duration time of salvage ADT, months (IQR)

41 (22 - 66)

46 (27 - 73.25)

0.1326

  1. ADT, androgen deprivation therapy; PSA, prostate-specific antigen; IQR, interquartile range.